The series of preclinical data and Phase 1 trials for SOD1 ASO have collectively demonstrated the safety of intrathecal administration and its efficacy in rodents, established protocols and evaluation methods for intrathecal administration studies, and indicated the feasibility of ASO therapy for CNS disorders [74]. This evidence concerns the gene SOD1 and central nervous system disorder.